These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25231113)

  • 1. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival.
    Moreno MJ; Bosch R; Dieguez-Gonzalez R; Novelli S; Mozos A; Gallardo A; Pavón MÁ; Céspedes MV; Grañena A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
    J Pathol; 2015 Feb; 235(3):445-55. PubMed ID: 25231113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis.
    Moreno MJ; Gallardo A; Novelli S; Mozos A; Aragó M; Pavón MÁ; Céspedes MV; Pallarès V; Falgàs A; Alcoceba M; Blanco O; Gonzalez-Díaz M; Sierra J; Mangues R; Casanova I
    PLoS One; 2018; 13(6):e0198789. PubMed ID: 29920526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The
    Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
    Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
    Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ibrutinib inhibits mesenchymal stem cells-mediated drug resistance in diffuse large B-cell lymphoma].
    Wu L; Zhang YZ; Xia B; Li XW; Yuan T; Tian C; Zhao HF; Yu Y; Sotomayor E
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1036-1042. PubMed ID: 29365396
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.
    Xu ZZ; Shen JK; Zhao SQ; Li JM
    Leuk Lymphoma; 2018 Jun; 59(6):1451-1460. PubMed ID: 28952842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective delivery of T22-PE24-H6 to CXCR4
    Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
    Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy.
    Shin HC; Seo J; Kang BW; Moon JH; Chae YS; Lee SJ; Lee YJ; Han S; Seo SK; Kim JG; Sohn SK; Park TI
    Korean J Intern Med; 2014 Nov; 29(6):785-92. PubMed ID: 25378977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant NEAT1_1 expression may be a predictive marker of poor prognosis in diffuse large B cell lymphoma.
    Deng L; Jiang L; Tseng KF; Liu Y; Zhang X; Dong R; Lu Z; Wang X
    Cancer Biomark; 2018; 23(2):157-164. PubMed ID: 30175971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges.
    Du H; Gao L; Luan J; Zhang H; Xiao T
    Acta Haematol; 2019; 142(2):64-70. PubMed ID: 31096215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of CXCR4 Upregulation in Diffuse Large B-Cell Lymphoma Associated with Prognostic Significance and Clinicopathological Characteristics.
    Zhang YA; Yang X; Yao J; Ren Y; Liu P
    Dis Markers; 2022; 2022():3276925. PubMed ID: 35774848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.
    Bertolini F; Dell'Agnola C; Mancuso P; Rabascio C; Burlini A; Monestiroli S; Gobbi A; Pruneri G; Martinelli G
    Cancer Res; 2002 Jun; 62(11):3106-12. PubMed ID: 12036921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 and CCR7 Expression in Primary Nodal Diffuse Large B-Cell Lymphoma-A Clinical and Immunohistochemical Study.
    Du H; Zhang L; Li G; Liu W; Tang W; Zhang H; Luan J; Gao L; Wang X
    Am J Med Sci; 2019 Apr; 357(4):302-310. PubMed ID: 30904045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma.
    Yang W; Wang C; Lin Y; Liu Q; Yu LX; Tang L; Yan HX; Fu J; Chen Y; Zhang HL; Tang L; Zheng LY; He YQ; Li YQ; Wu FQ; Zou SS; Li Z; Wu MC; Feng GS; Wang HY
    J Hepatol; 2012 Sep; 57(3):613-20. PubMed ID: 22612999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CXCR4 antagonist inhibits perineural invasion of adenoid cystic carcinoma.
    Jeong WJ; Choi IJ; Park MW; An SY; Jeon EH; Paik JH; Sung MW; Ahn SH
    J Clin Pathol; 2014 Nov; 67(11):992-8. PubMed ID: 25118295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
    Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
    Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling.
    Arnaud MP; Vallée A; Robert G; Bonneau J; Leroy C; Varin-Blank N; Rio AG; Troadec MB; Galibert MD; Gandemer V
    Blood; 2015 Oct; 126(15):1802-12. PubMed ID: 26320102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
    Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
    Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression.
    Lee Y; Kim SJ; Park HD; Park EH; Huang SM; Jeon SB; Kim JM; Lim DS; Koh SS
    Oncogene; 2010 Jan; 29(1):56-67. PubMed ID: 19784070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.